MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: NYSE:BSX), a global medical technology leader, has announced the immediate election of Dr. Cheryl Pegus to its board of directors.
Dr. Pegus brings over two decades of experience in clinical and business leadership roles to the Boston Scientific board. Her career spans positions at Morgan Health, where she worked on improving healthcare quality and equity, to executive roles at Walmart (NYSE:WMT) and Cambia Health Solutions. Additionally, she has held significant roles at Walgreens, SymCare Personalized Health Solutions, Inc., Pfizer (NYSE:PFE), and Aetna.
As a cardiologist, Dr. Pegus began her career in private practice. She has served as board chair for the Association of Black Cardiologists and currently serves on the board of the American Heart Association. Dr. Pegus is also a co-founder of A New Beat, an organization aimed at enhancing the cardiovascular health and careers of women and underrepresented minorities. Her academic credentials include a B.A. from Brandeis University, an M.D. from Weill Cornell Medical College, and an M.P.H. from Columbia University Mailman School of Public Health.
Mike Mahoney, CEO and chairman of Boston Scientific, expressed confidence in Dr. Pegus's ability to contribute to the company's growth and commitment to healthcare innovation. He highlighted her passion for healthcare access and improving patient outcomes.
Boston Scientific has a history of over 40 years in the development of medical technologies that address patient needs and reduce healthcare costs. The company's product portfolio supports the diagnosis and treatment of complex diseases across several medical specialties.
InvestingPro Insights
Boston Scientific Corporation (NYSE: BSX), known for its significant impact in the field of medical technology, has shown promising financial indicators that could interest investors. According to recent data from InvestingPro, Boston Scientific is expected to see net income growth this year. This projection aligns with the company's ongoing efforts to innovate and expand its product portfolio, potentially leading to increased profitability.
In addition, the company is trading at a low Price-to-Earnings (P/E) ratio relative to its near-term earnings growth, which could suggest that BSX is undervalued given its future earnings potential. This financial metric is particularly noteworthy for investors looking for growth opportunities in the healthcare sector. Furthermore, 19 analysts have revised their earnings estimates upwards for the upcoming period, indicating a positive outlook on the company's financial performance.
Boston Scientific's strategic moves, including the recent addition of Dr. Cheryl Pegus to its board, may continue to steer the company towards a strong market position. For investors seeking more in-depth analysis, there are additional InvestingPro Tips available, which highlight the company's status as a prominent player in the Healthcare Equipment & Supplies industry and its ability to manage cash flows and debt effectively. To explore these insights and more, interested parties can visit InvestingPro and use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
InvestingPro Data:
- Net Income Growth: Expected increase in the current year
- P/E Ratio: Trading at a low ratio relative to near-term earnings growth
- Analyst Sentiment: 19 analysts have revised their earnings estimates upwards
With Boston Scientific's strong foundation in medical technology and a positive financial outlook, the company is poised for continued success in the dynamic healthcare market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.